Formosa Laboratories, Inc. (4746.TW)
TWD 71.9
(-0.96%)
TWD 71.9
(-0.96%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.03 Billion TWD | 22.82% |
| 2022 | 1.65 Billion TWD | -14.05% |
| 2021 | 1.93 Billion TWD | 3.28% |
| 2020 | 1.86 Billion TWD | -25.42% |
| 2019 | 2.5 Billion TWD | -4.07% |
| 2018 | 2.61 Billion TWD | 348.35% |
| 2017 | 582.72 Million TWD | -13.23% |
| 2016 | 671.55 Million TWD | -37.58% |
| 2015 | 1.07 Billion TWD | -6.82% |
| 2014 | 1.15 Billion TWD | 70.74% |
| 2013 | 676.26 Million TWD | -28.13% |
| 2012 | 941 Million TWD | 0.0% |
| 2011 | - TWD | -100.0% |
| 2010 | 150 Million TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.28 Billion TWD | 10.06% |
| 2024 Q1 | 2.09 Billion TWD | 1.99% |
| 2023 FY | 2.03 Billion TWD | 22.82% |
| 2023 Q4 | 2.03 Billion TWD | 0.56% |
| 2023 Q3 | 2.02 Billion TWD | -0.42% |
| 2023 Q2 | 2.03 Billion TWD | 10.37% |
| 2023 Q1 | 1.84 Billion TWD | 11.13% |
| 2022 Q1 | 1.85 Billion TWD | -3.88% |
| 2022 Q4 | 1.65 Billion TWD | -11.99% |
| 2022 Q2 | 1.93 Billion TWD | 4.28% |
| 2022 FY | 1.65 Billion TWD | -14.05% |
| 2022 Q3 | 1.88 Billion TWD | -2.57% |
| 2021 Q1 | 2.02 Billion TWD | 8.22% |
| 2021 Q2 | 2.13 Billion TWD | 5.62% |
| 2021 FY | 1.93 Billion TWD | 3.28% |
| 2021 Q3 | 2.27 Billion TWD | 6.48% |
| 2021 Q4 | 1.93 Billion TWD | -15.14% |
| 2020 FY | 1.86 Billion TWD | -25.42% |
| 2020 Q1 | 2.18 Billion TWD | -12.64% |
| 2020 Q3 | 1.39 Billion TWD | -41.04% |
| 2020 Q4 | 1.86 Billion TWD | 33.94% |
| 2020 Q2 | 2.36 Billion TWD | 8.1% |
| 2019 FY | 2.5 Billion TWD | -4.07% |
| 2019 Q4 | 2.5 Billion TWD | -1.56% |
| 2019 Q3 | 2.54 Billion TWD | -5.32% |
| 2019 Q2 | 2.68 Billion TWD | -0.98% |
| 2019 Q1 | 2.71 Billion TWD | 3.94% |
| 2018 Q3 | 1.97 Billion TWD | 101.92% |
| 2018 Q2 | 976.74 Million TWD | 30.45% |
| 2018 Q1 | 748.74 Million TWD | 28.49% |
| 2018 FY | 2.61 Billion TWD | 348.35% |
| 2018 Q4 | 2.61 Billion TWD | 32.47% |
| 2017 Q1 | 619.81 Million TWD | -7.7% |
| 2017 Q4 | 582.72 Million TWD | 12.78% |
| 2017 Q3 | 516.69 Million TWD | -1.22% |
| 2017 Q2 | 523.07 Million TWD | -15.61% |
| 2017 FY | 582.72 Million TWD | -13.23% |
| 2016 Q1 | 1.32 Billion TWD | 23.56% |
| 2016 Q4 | 671.55 Million TWD | -7.67% |
| 2016 Q2 | 1.19 Billion TWD | -9.87% |
| 2016 FY | 671.55 Million TWD | -37.58% |
| 2016 Q3 | 727.34 Million TWD | -39.3% |
| 2015 Q3 | 1.31 Billion TWD | 7.97% |
| 2015 FY | 1.07 Billion TWD | -6.82% |
| 2015 Q4 | 1.07 Billion TWD | -18.28% |
| 2015 Q2 | 1.21 Billion TWD | 16.63% |
| 2015 Q1 | 1.04 Billion TWD | -9.46% |
| 2014 Q2 | 702.15 Million TWD | -0.48% |
| 2014 Q1 | 705.53 Million TWD | 4.33% |
| 2014 Q4 | 1.15 Billion TWD | 2.32% |
| 2014 FY | 1.15 Billion TWD | 70.74% |
| 2014 Q3 | 1.12 Billion TWD | 60.72% |
| 2013 Q1 | 910.38 Million TWD | -3.25% |
| 2013 Q2 | 1.17 Billion TWD | 29.47% |
| 2013 Q3 | 970.13 Million TWD | -17.7% |
| 2013 Q4 | 676.26 Million TWD | -30.29% |
| 2013 FY | 676.26 Million TWD | -28.13% |
| 2012 Q4 | 941 Million TWD | 100.21% |
| 2012 Q1 | 70 Million TWD | 0.0% |
| 2012 Q2 | 330 Million TWD | 371.43% |
| 2012 FY | 941 Million TWD | 0.0% |
| 2012 Q3 | 470 Million TWD | 42.42% |
| 2011 Q3 | 88 Million TWD | 29.41% |
| 2011 Q4 | - TWD | -100.0% |
| 2011 Q1 | 84.25 Million TWD | -43.83% |
| 2011 Q2 | 68 Million TWD | -19.29% |
| 2011 FY | - TWD | -100.0% |
| 2010 FY | 150 Million TWD | 0.0% |
| 2010 Q4 | 150 Million TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 136.36 Million TWD | -1394.498% |
| Standard Chem & Pharm CO., LTD. | 222.97 Million TWD | -813.966% |
| Maywufa Company Ltd. | 438.97 Million TWD | -364.238% |
| ScinoPharm Taiwan, Ltd. | 570.23 Million TWD | -257.381% |
| Lotus Pharmaceutical Co., Ltd. | 9.51 Billion TWD | 78.592% |
| LIWANLI Innovation Co., Ltd. | 361 Thousand TWD | -564414.404% |
| YungShin Global Holding Corporation | 241.99 Million TWD | -742.12% |
| PhytoHealth Corporation | 17.46 Million TWD | -11571.804% |
| SCI Pharmtech, Inc. | 845.52 Million TWD | -141.021% |
| PharmaEssentia Corporation | 954.99 Million TWD | -113.393% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | 41.557% |